nodes	percent_of_prediction	percent_of_DWPC	metapath
Auranofin—ALB—breast cancer	0.328	1	CbGaD
Auranofin—ALB—Irinotecan—breast cancer	0.0117	0.402	CbGbCtD
Auranofin—ALB—Fluorouracil—breast cancer	0.0113	0.386	CbGbCtD
Auranofin—PRDX5—nipple—breast cancer	0.00924	0.0782	CbGeAlD
Auranofin—PRDX5—embryo—breast cancer	0.00763	0.0646	CbGeAlD
Auranofin—PRDX5—epithelium—breast cancer	0.00622	0.0527	CbGeAlD
Auranofin—ALB—Methotrexate—breast cancer	0.00621	0.213	CbGbCtD
Auranofin—PRDX5—skin of body—breast cancer	0.00592	0.0501	CbGeAlD
Auranofin—PRDX5—endometrium—breast cancer	0.00558	0.0472	CbGeAlD
Auranofin—IKBKB—nipple—breast cancer	0.00547	0.0463	CbGeAlD
Auranofin—PRDX5—uterus—breast cancer	0.00514	0.0435	CbGeAlD
Auranofin—PRDX5—pituitary gland—breast cancer	0.00505	0.0428	CbGeAlD
Auranofin—PRDX5—adipose tissue—breast cancer	0.00503	0.0426	CbGeAlD
Auranofin—PRDX5—female reproductive system—breast cancer	0.00462	0.0391	CbGeAlD
Auranofin—IKBKB—embryo—breast cancer	0.00452	0.0382	CbGeAlD
Auranofin—PRDX5—adrenal gland—breast cancer	0.00451	0.0382	CbGeAlD
Auranofin—PRDX5—bone marrow—breast cancer	0.00436	0.0369	CbGeAlD
Auranofin—PRDX5—female gonad—breast cancer	0.00421	0.0356	CbGeAlD
Auranofin—PRDX5—endocrine gland—breast cancer	0.00391	0.0331	CbGeAlD
Auranofin—ALB—mammary gland—breast cancer	0.00386	0.0327	CbGeAlD
Auranofin—IKBKB—skin of body—breast cancer	0.0035	0.0297	CbGeAlD
Auranofin—IKBKB—endometrium—breast cancer	0.0033	0.028	CbGeAlD
Auranofin—IKBKB—uterus—breast cancer	0.00304	0.0258	CbGeAlD
Auranofin—IKBKB—pituitary gland—breast cancer	0.00299	0.0253	CbGeAlD
Auranofin—IKBKB—adipose tissue—breast cancer	0.00298	0.0252	CbGeAlD
Auranofin—IKBKB—female reproductive system—breast cancer	0.00274	0.0232	CbGeAlD
Auranofin—PRDX5—lymph node—breast cancer	0.0027	0.0229	CbGeAlD
Auranofin—IKBKB—adrenal gland—breast cancer	0.00267	0.0226	CbGeAlD
Auranofin—IKBKB—female gonad—breast cancer	0.00249	0.0211	CbGeAlD
Auranofin—IKBKB—endocrine gland—breast cancer	0.00232	0.0196	CbGeAlD
Auranofin—IKBKB—lymph node—breast cancer	0.0016	0.0136	CbGeAlD
Auranofin—ALB—adrenal gland—breast cancer	0.00156	0.0132	CbGeAlD
Auranofin—ALB—lymph node—breast cancer	0.000935	0.00791	CbGeAlD
Auranofin—Jaundice—Capecitabine—breast cancer	0.000274	0.00105	CcSEcCtD
Auranofin—Stomatitis—Capecitabine—breast cancer	0.000274	0.00105	CcSEcCtD
Auranofin—Conjunctivitis—Capecitabine—breast cancer	0.000274	0.00104	CcSEcCtD
Auranofin—Dyspepsia—Thiotepa—breast cancer	0.000273	0.00104	CcSEcCtD
Auranofin—Alopecia—Paclitaxel—breast cancer	0.000272	0.00104	CcSEcCtD
Auranofin—Vomiting—Chlorambucil—breast cancer	0.000271	0.00104	CcSEcCtD
Auranofin—Agranulocytosis—Docetaxel—breast cancer	0.000271	0.00103	CcSEcCtD
Auranofin—Decreased appetite—Thiotepa—breast cancer	0.00027	0.00103	CcSEcCtD
Auranofin—Dermatitis exfoliative—Epirubicin—breast cancer	0.00027	0.00103	CcSEcCtD
Auranofin—Pruritus—Tamoxifen—breast cancer	0.000269	0.00103	CcSEcCtD
Auranofin—Haematuria—Capecitabine—breast cancer	0.000268	0.00102	CcSEcCtD
Auranofin—Diarrhoea—Vinblastine—breast cancer	0.000268	0.00102	CcSEcCtD
Auranofin—Gastrointestinal pain—Vinorelbine—breast cancer	0.000266	0.00101	CcSEcCtD
Auranofin—Constipation—Thiotepa—breast cancer	0.000266	0.00101	CcSEcCtD
Auranofin—Flatulence—Paclitaxel—breast cancer	0.000264	0.00101	CcSEcCtD
Auranofin—Pruritus—Melphalan—breast cancer	0.000263	0.001	CcSEcCtD
Auranofin—Agranulocytosis—Capecitabine—breast cancer	0.000263	0.001	CcSEcCtD
Auranofin—Thrombocytopenia—Irinotecan—breast cancer	0.000263	0.001	CcSEcCtD
Auranofin—Thrombocytopenia—Mitoxantrone—breast cancer	0.000263	0.001	CcSEcCtD
Auranofin—Dysgeusia—Paclitaxel—breast cancer	0.000262	0.001	CcSEcCtD
Auranofin—Diarrhoea—Tamoxifen—breast cancer	0.00026	0.000992	CcSEcCtD
Auranofin—Urticaria—Vinorelbine—breast cancer	0.000258	0.000985	CcSEcCtD
Auranofin—Abdominal pain—Vinorelbine—breast cancer	0.000257	0.00098	CcSEcCtD
Auranofin—Pruritus—Goserelin—breast cancer	0.000257	0.000979	CcSEcCtD
Auranofin—Thrombocytopenia—Gemcitabine—breast cancer	0.000256	0.000975	CcSEcCtD
Auranofin—Anorexia—Irinotecan—breast cancer	0.000256	0.000975	CcSEcCtD
Auranofin—Anorexia—Mitoxantrone—breast cancer	0.000256	0.000975	CcSEcCtD
Auranofin—Diarrhoea—Melphalan—breast cancer	0.000255	0.000971	CcSEcCtD
Auranofin—Gastrointestinal haemorrhage—Epirubicin—breast cancer	0.000254	0.00097	CcSEcCtD
Auranofin—Gastrointestinal pain—Thiotepa—breast cancer	0.000254	0.000968	CcSEcCtD
Auranofin—Nausea—Chlorambucil—breast cancer	0.000254	0.000967	CcSEcCtD
Auranofin—Thrombocytopenia—Fluorouracil—breast cancer	0.000251	0.000959	CcSEcCtD
Auranofin—Visual impairment—Docetaxel—breast cancer	0.000251	0.000959	CcSEcCtD
Auranofin—Dermatitis exfoliative—Doxorubicin—breast cancer	0.000249	0.000951	CcSEcCtD
Auranofin—Anorexia—Gemcitabine—breast cancer	0.000249	0.000949	CcSEcCtD
Auranofin—Vomiting—Vinblastine—breast cancer	0.000249	0.000949	CcSEcCtD
Auranofin—Diarrhoea—Goserelin—breast cancer	0.000248	0.000947	CcSEcCtD
Auranofin—Anaemia—Paclitaxel—breast cancer	0.000248	0.000944	CcSEcCtD
Auranofin—Urticaria—Thiotepa—breast cancer	0.000247	0.000941	CcSEcCtD
Auranofin—Abdominal pain—Thiotepa—breast cancer	0.000245	0.000936	CcSEcCtD
Auranofin—Angioedema—Paclitaxel—breast cancer	0.000245	0.000934	CcSEcCtD
Auranofin—Anorexia—Fluorouracil—breast cancer	0.000245	0.000933	CcSEcCtD
Auranofin—Eye disorder—Docetaxel—breast cancer	0.000244	0.00093	CcSEcCtD
Auranofin—Visual impairment—Capecitabine—breast cancer	0.000243	0.000928	CcSEcCtD
Auranofin—Vomiting—Tamoxifen—breast cancer	0.000242	0.000921	CcSEcCtD
Auranofin—Leukopenia—Paclitaxel—breast cancer	0.00024	0.000915	CcSEcCtD
Auranofin—Rash—Tamoxifen—breast cancer	0.00024	0.000914	CcSEcCtD
Auranofin—Dermatitis—Tamoxifen—breast cancer	0.000239	0.000913	CcSEcCtD
Auranofin—Vomiting—Melphalan—breast cancer	0.000237	0.000902	CcSEcCtD
Auranofin—Eye disorder—Capecitabine—breast cancer	0.000236	0.0009	CcSEcCtD
Auranofin—Dyspepsia—Irinotecan—breast cancer	0.000236	0.0009	CcSEcCtD
Auranofin—Dyspepsia—Mitoxantrone—breast cancer	0.000236	0.0009	CcSEcCtD
Auranofin—Gastrointestinal haemorrhage—Doxorubicin—breast cancer	0.000235	0.000897	CcSEcCtD
Auranofin—Rash—Melphalan—breast cancer	0.000235	0.000895	CcSEcCtD
Auranofin—Dermatitis—Melphalan—breast cancer	0.000234	0.000894	CcSEcCtD
Auranofin—Decreased appetite—Mitoxantrone—breast cancer	0.000233	0.000889	CcSEcCtD
Auranofin—Decreased appetite—Irinotecan—breast cancer	0.000233	0.000889	CcSEcCtD
Auranofin—Eosinophilia—Methotrexate—breast cancer	0.000233	0.000887	CcSEcCtD
Auranofin—Nausea—Vinblastine—breast cancer	0.000232	0.000886	CcSEcCtD
Auranofin—Vomiting—Goserelin—breast cancer	0.000231	0.00088	CcSEcCtD
Auranofin—Alopecia—Docetaxel—breast cancer	0.000231	0.000879	CcSEcCtD
Auranofin—Pruritus—Vinorelbine—breast cancer	0.00023	0.000877	CcSEcCtD
Auranofin—Constipation—Irinotecan—breast cancer	0.000229	0.000874	CcSEcCtD
Auranofin—Constipation—Mitoxantrone—breast cancer	0.000229	0.000874	CcSEcCtD
Auranofin—Rash—Goserelin—breast cancer	0.000229	0.000873	CcSEcCtD
Auranofin—Dermatitis—Goserelin—breast cancer	0.000229	0.000872	CcSEcCtD
Auranofin—Decreased appetite—Gemcitabine—breast cancer	0.000227	0.000866	CcSEcCtD
Auranofin—Dyspepsia—Fluorouracil—breast cancer	0.000226	0.000862	CcSEcCtD
Auranofin—Nausea—Tamoxifen—breast cancer	0.000226	0.000861	CcSEcCtD
Auranofin—Constipation—Gemcitabine—breast cancer	0.000223	0.000852	CcSEcCtD
Auranofin—Decreased appetite—Fluorouracil—breast cancer	0.000223	0.000851	CcSEcCtD
Auranofin—Alopecia—Capecitabine—breast cancer	0.000223	0.000851	CcSEcCtD
Auranofin—Pancytopenia—Methotrexate—breast cancer	0.000223	0.000851	CcSEcCtD
Auranofin—Diarrhoea—Vinorelbine—breast cancer	0.000222	0.000848	CcSEcCtD
Auranofin—Dysgeusia—Docetaxel—breast cancer	0.000222	0.000848	CcSEcCtD
Auranofin—Nausea—Melphalan—breast cancer	0.000221	0.000843	CcSEcCtD
Auranofin—Dysphagia—Epirubicin—breast cancer	0.00022	0.000838	CcSEcCtD
Auranofin—Neutropenia—Methotrexate—breast cancer	0.00022	0.000838	CcSEcCtD
Auranofin—Pruritus—Thiotepa—breast cancer	0.00022	0.000838	CcSEcCtD
Auranofin—Gastrointestinal pain—Irinotecan—breast cancer	0.000219	0.000836	CcSEcCtD
Auranofin—Gastrointestinal pain—Mitoxantrone—breast cancer	0.000219	0.000836	CcSEcCtD
Auranofin—Eosinophilia—Epirubicin—breast cancer	0.000218	0.00083	CcSEcCtD
Auranofin—Flatulence—Capecitabine—breast cancer	0.000217	0.000826	CcSEcCtD
Auranofin—Nausea—Goserelin—breast cancer	0.000216	0.000822	CcSEcCtD
Auranofin—Dysgeusia—Capecitabine—breast cancer	0.000215	0.000821	CcSEcCtD
Auranofin—Thrombocytopenia—Paclitaxel—breast cancer	0.000214	0.000816	CcSEcCtD
Auranofin—Urticaria—Mitoxantrone—breast cancer	0.000213	0.000812	CcSEcCtD
Auranofin—Diarrhoea—Thiotepa—breast cancer	0.000212	0.00081	CcSEcCtD
Auranofin—Abdominal pain—Mitoxantrone—breast cancer	0.000212	0.000808	CcSEcCtD
Auranofin—Abdominal pain—Irinotecan—breast cancer	0.000212	0.000808	CcSEcCtD
Auranofin—Anaemia—Docetaxel—breast cancer	0.00021	0.0008	CcSEcCtD
Auranofin—Pancytopenia—Epirubicin—breast cancer	0.000209	0.000796	CcSEcCtD
Auranofin—Anorexia—Paclitaxel—breast cancer	0.000208	0.000795	CcSEcCtD
Auranofin—Vomiting—Vinorelbine—breast cancer	0.000207	0.000788	CcSEcCtD
Auranofin—Neutropenia—Epirubicin—breast cancer	0.000206	0.000784	CcSEcCtD
Auranofin—Rash—Vinorelbine—breast cancer	0.000205	0.000782	CcSEcCtD
Auranofin—Dermatitis—Vinorelbine—breast cancer	0.000205	0.000781	CcSEcCtD
Auranofin—Stomatitis—Methotrexate—breast cancer	0.000204	0.000779	CcSEcCtD
Auranofin—Urticaria—Fluorouracil—breast cancer	0.000204	0.000778	CcSEcCtD
Auranofin—Conjunctivitis—Methotrexate—breast cancer	0.000204	0.000776	CcSEcCtD
Auranofin—Dysphagia—Doxorubicin—breast cancer	0.000203	0.000776	CcSEcCtD
Auranofin—Leukopenia—Docetaxel—breast cancer	0.000203	0.000775	CcSEcCtD
Auranofin—Anaemia—Capecitabine—breast cancer	0.000203	0.000775	CcSEcCtD
Auranofin—Eosinophilia—Doxorubicin—breast cancer	0.000201	0.000768	CcSEcCtD
Auranofin—Haematuria—Methotrexate—breast cancer	0.0002	0.000762	CcSEcCtD
Auranofin—Weight decreased—Epirubicin—breast cancer	0.000199	0.000758	CcSEcCtD
Auranofin—Vomiting—Thiotepa—breast cancer	0.000197	0.000753	CcSEcCtD
Auranofin—Leukopenia—Capecitabine—breast cancer	0.000197	0.000751	CcSEcCtD
Auranofin—Rash—Thiotepa—breast cancer	0.000196	0.000747	CcSEcCtD
Auranofin—Dermatitis—Thiotepa—breast cancer	0.000196	0.000746	CcSEcCtD
Auranofin—Agranulocytosis—Methotrexate—breast cancer	0.000195	0.000745	CcSEcCtD
Auranofin—Pancytopenia—Doxorubicin—breast cancer	0.000193	0.000737	CcSEcCtD
Auranofin—Nausea—Vinorelbine—breast cancer	0.000193	0.000736	CcSEcCtD
Auranofin—Dyspepsia—Paclitaxel—breast cancer	0.000193	0.000734	CcSEcCtD
Auranofin—Neuropathy peripheral—Epirubicin—breast cancer	0.000192	0.000733	CcSEcCtD
Auranofin—Jaundice—Epirubicin—breast cancer	0.000191	0.000729	CcSEcCtD
Auranofin—Stomatitis—Epirubicin—breast cancer	0.000191	0.000729	CcSEcCtD
Auranofin—Conjunctivitis—Epirubicin—breast cancer	0.000191	0.000727	CcSEcCtD
Auranofin—Neutropenia—Doxorubicin—breast cancer	0.00019	0.000725	CcSEcCtD
Auranofin—Decreased appetite—Paclitaxel—breast cancer	0.00019	0.000725	CcSEcCtD
Auranofin—Constipation—Paclitaxel—breast cancer	0.000187	0.000713	CcSEcCtD
Auranofin—Haematuria—Epirubicin—breast cancer	0.000187	0.000713	CcSEcCtD
Auranofin—Pruritus—Gemcitabine—breast cancer	0.000185	0.000705	CcSEcCtD
Auranofin—Nausea—Thiotepa—breast cancer	0.000184	0.000703	CcSEcCtD
Auranofin—Weight decreased—Doxorubicin—breast cancer	0.000184	0.000702	CcSEcCtD
Auranofin—Diarrhoea—Mitoxantrone—breast cancer	0.000183	0.0007	CcSEcCtD
Auranofin—Diarrhoea—Irinotecan—breast cancer	0.000183	0.0007	CcSEcCtD
Auranofin—Agranulocytosis—Epirubicin—breast cancer	0.000183	0.000698	CcSEcCtD
Auranofin—Pruritus—Fluorouracil—breast cancer	0.000182	0.000693	CcSEcCtD
Auranofin—Thrombocytopenia—Docetaxel—breast cancer	0.000182	0.000692	CcSEcCtD
Auranofin—Visual impairment—Methotrexate—breast cancer	0.000181	0.000691	CcSEcCtD
Auranofin—Gastrointestinal pain—Paclitaxel—breast cancer	0.000179	0.000682	CcSEcCtD
Auranofin—Diarrhoea—Gemcitabine—breast cancer	0.000179	0.000681	CcSEcCtD
Auranofin—Neuropathy peripheral—Doxorubicin—breast cancer	0.000178	0.000678	CcSEcCtD
Auranofin—Stomatitis—Doxorubicin—breast cancer	0.000177	0.000674	CcSEcCtD
Auranofin—Jaundice—Doxorubicin—breast cancer	0.000177	0.000674	CcSEcCtD
Auranofin—Anorexia—Docetaxel—breast cancer	0.000177	0.000674	CcSEcCtD
Auranofin—Conjunctivitis—Doxorubicin—breast cancer	0.000176	0.000672	CcSEcCtD
Auranofin—Eye disorder—Methotrexate—breast cancer	0.000176	0.00067	CcSEcCtD
Auranofin—Diarrhoea—Fluorouracil—breast cancer	0.000176	0.00067	CcSEcCtD
Auranofin—Thrombocytopenia—Capecitabine—breast cancer	0.000176	0.00067	CcSEcCtD
Auranofin—Urticaria—Paclitaxel—breast cancer	0.000174	0.000662	CcSEcCtD
Auranofin—Haematuria—Doxorubicin—breast cancer	0.000173	0.000659	CcSEcCtD
Auranofin—Abdominal pain—Paclitaxel—breast cancer	0.000173	0.000659	CcSEcCtD
Auranofin—Anorexia—Capecitabine—breast cancer	0.000171	0.000652	CcSEcCtD
Auranofin—Vomiting—Mitoxantrone—breast cancer	0.000171	0.00065	CcSEcCtD
Auranofin—Vomiting—Irinotecan—breast cancer	0.000171	0.00065	CcSEcCtD
Auranofin—Visual impairment—Epirubicin—breast cancer	0.00017	0.000647	CcSEcCtD
Auranofin—Agranulocytosis—Doxorubicin—breast cancer	0.000169	0.000645	CcSEcCtD
Auranofin—Rash—Irinotecan—breast cancer	0.000169	0.000645	CcSEcCtD
Auranofin—Rash—Mitoxantrone—breast cancer	0.000169	0.000645	CcSEcCtD
Auranofin—Dermatitis—Irinotecan—breast cancer	0.000169	0.000644	CcSEcCtD
Auranofin—Dermatitis—Mitoxantrone—breast cancer	0.000169	0.000644	CcSEcCtD
Auranofin—Alopecia—Methotrexate—breast cancer	0.000166	0.000634	CcSEcCtD
Auranofin—Vomiting—Gemcitabine—breast cancer	0.000166	0.000633	CcSEcCtD
Auranofin—Rash—Gemcitabine—breast cancer	0.000165	0.000628	CcSEcCtD
Auranofin—Dermatitis—Gemcitabine—breast cancer	0.000165	0.000627	CcSEcCtD
Auranofin—Eye disorder—Epirubicin—breast cancer	0.000164	0.000627	CcSEcCtD
Auranofin—Vomiting—Fluorouracil—breast cancer	0.000163	0.000623	CcSEcCtD
Auranofin—Dyspepsia—Docetaxel—breast cancer	0.000163	0.000622	CcSEcCtD
Auranofin—Rash—Fluorouracil—breast cancer	0.000162	0.000617	CcSEcCtD
Auranofin—Dermatitis—Fluorouracil—breast cancer	0.000162	0.000617	CcSEcCtD
Auranofin—Decreased appetite—Docetaxel—breast cancer	0.000161	0.000614	CcSEcCtD
Auranofin—Dysgeusia—Methotrexate—breast cancer	0.00016	0.000611	CcSEcCtD
Auranofin—Nausea—Mitoxantrone—breast cancer	0.000159	0.000607	CcSEcCtD
Auranofin—Nausea—Irinotecan—breast cancer	0.000159	0.000607	CcSEcCtD
Auranofin—Constipation—Docetaxel—breast cancer	0.000159	0.000604	CcSEcCtD
Auranofin—Dyspepsia—Capecitabine—breast cancer	0.000158	0.000602	CcSEcCtD
Auranofin—Visual impairment—Doxorubicin—breast cancer	0.000157	0.000598	CcSEcCtD
Auranofin—Decreased appetite—Capecitabine—breast cancer	0.000156	0.000595	CcSEcCtD
Auranofin—Alopecia—Epirubicin—breast cancer	0.000156	0.000593	CcSEcCtD
Auranofin—Nausea—Gemcitabine—breast cancer	0.000155	0.000592	CcSEcCtD
Auranofin—Pruritus—Paclitaxel—breast cancer	0.000155	0.00059	CcSEcCtD
Auranofin—Constipation—Capecitabine—breast cancer	0.000153	0.000585	CcSEcCtD
Auranofin—Nausea—Fluorouracil—breast cancer	0.000153	0.000582	CcSEcCtD
Auranofin—Eye disorder—Doxorubicin—breast cancer	0.000152	0.00058	CcSEcCtD
Auranofin—Gastrointestinal pain—Docetaxel—breast cancer	0.000152	0.000578	CcSEcCtD
Auranofin—Anaemia—Methotrexate—breast cancer	0.000151	0.000577	CcSEcCtD
Auranofin—Flatulence—Epirubicin—breast cancer	0.000151	0.000576	CcSEcCtD
Auranofin—Dysgeusia—Epirubicin—breast cancer	0.00015	0.000572	CcSEcCtD
Auranofin—Diarrhoea—Paclitaxel—breast cancer	0.00015	0.000571	CcSEcCtD
Auranofin—Gastrointestinal pain—Capecitabine—breast cancer	0.000147	0.00056	CcSEcCtD
Auranofin—Abdominal pain—Docetaxel—breast cancer	0.000147	0.000559	CcSEcCtD
Auranofin—Leukopenia—Methotrexate—breast cancer	0.000147	0.000559	CcSEcCtD
Auranofin—Alopecia—Doxorubicin—breast cancer	0.000144	0.000549	CcSEcCtD
Auranofin—Urticaria—Capecitabine—breast cancer	0.000143	0.000544	CcSEcCtD
Auranofin—Abdominal pain—Capecitabine—breast cancer	0.000142	0.000541	CcSEcCtD
Auranofin—Anaemia—Epirubicin—breast cancer	0.000142	0.00054	CcSEcCtD
Auranofin—Flatulence—Doxorubicin—breast cancer	0.00014	0.000533	CcSEcCtD
Auranofin—Vomiting—Paclitaxel—breast cancer	0.000139	0.00053	CcSEcCtD
Auranofin—Dysgeusia—Doxorubicin—breast cancer	0.000139	0.000529	CcSEcCtD
Auranofin—Rash—Paclitaxel—breast cancer	0.000138	0.000526	CcSEcCtD
Auranofin—Dermatitis—Paclitaxel—breast cancer	0.000138	0.000525	CcSEcCtD
Auranofin—Leukopenia—Epirubicin—breast cancer	0.000137	0.000523	CcSEcCtD
Auranofin—Pruritus—Docetaxel—breast cancer	0.000131	0.0005	CcSEcCtD
Auranofin—Anaemia—Doxorubicin—breast cancer	0.000131	0.0005	CcSEcCtD
Auranofin—Thrombocytopenia—Methotrexate—breast cancer	0.000131	0.000499	CcSEcCtD
Auranofin—Nausea—Paclitaxel—breast cancer	0.00013	0.000495	CcSEcCtD
Auranofin—Anorexia—Methotrexate—breast cancer	0.000127	0.000486	CcSEcCtD
Auranofin—Pruritus—Capecitabine—breast cancer	0.000127	0.000484	CcSEcCtD
Auranofin—Leukopenia—Doxorubicin—breast cancer	0.000127	0.000484	CcSEcCtD
Auranofin—Diarrhoea—Docetaxel—breast cancer	0.000127	0.000484	CcSEcCtD
Auranofin—Diarrhoea—Capecitabine—breast cancer	0.000123	0.000468	CcSEcCtD
Auranofin—Thrombocytopenia—Epirubicin—breast cancer	0.000122	0.000467	CcSEcCtD
Auranofin—Anorexia—Epirubicin—breast cancer	0.000119	0.000454	CcSEcCtD
Auranofin—Vomiting—Docetaxel—breast cancer	0.000118	0.000449	CcSEcCtD
Auranofin—Dyspepsia—Methotrexate—breast cancer	0.000118	0.000448	CcSEcCtD
Auranofin—Rash—Docetaxel—breast cancer	0.000117	0.000446	CcSEcCtD
Auranofin—Dermatitis—Docetaxel—breast cancer	0.000117	0.000445	CcSEcCtD
Auranofin—Decreased appetite—Methotrexate—breast cancer	0.000116	0.000443	CcSEcCtD
Auranofin—Vomiting—Capecitabine—breast cancer	0.000114	0.000435	CcSEcCtD
Auranofin—Thrombocytopenia—Doxorubicin—breast cancer	0.000113	0.000432	CcSEcCtD
Auranofin—Rash—Capecitabine—breast cancer	0.000113	0.000431	CcSEcCtD
Auranofin—Dermatitis—Capecitabine—breast cancer	0.000113	0.000431	CcSEcCtD
Auranofin—Anorexia—Doxorubicin—breast cancer	0.00011	0.00042	CcSEcCtD
Auranofin—Nausea—Docetaxel—breast cancer	0.00011	0.00042	CcSEcCtD
Auranofin—Dyspepsia—Epirubicin—breast cancer	0.00011	0.00042	CcSEcCtD
Auranofin—Gastrointestinal pain—Methotrexate—breast cancer	0.000109	0.000417	CcSEcCtD
Auranofin—Decreased appetite—Epirubicin—breast cancer	0.000109	0.000414	CcSEcCtD
Auranofin—Constipation—Epirubicin—breast cancer	0.000107	0.000408	CcSEcCtD
Auranofin—Nausea—Capecitabine—breast cancer	0.000107	0.000406	CcSEcCtD
Auranofin—Urticaria—Methotrexate—breast cancer	0.000106	0.000405	CcSEcCtD
Auranofin—Abdominal pain—Methotrexate—breast cancer	0.000106	0.000403	CcSEcCtD
Auranofin—Gastrointestinal pain—Epirubicin—breast cancer	0.000102	0.00039	CcSEcCtD
Auranofin—Dyspepsia—Doxorubicin—breast cancer	0.000102	0.000388	CcSEcCtD
Auranofin—Decreased appetite—Doxorubicin—breast cancer	0.000101	0.000383	CcSEcCtD
Auranofin—Urticaria—Epirubicin—breast cancer	9.93e-05	0.000379	CcSEcCtD
Auranofin—Constipation—Doxorubicin—breast cancer	9.89e-05	0.000377	CcSEcCtD
Auranofin—Abdominal pain—Epirubicin—breast cancer	9.88e-05	0.000377	CcSEcCtD
Auranofin—Gastrointestinal pain—Doxorubicin—breast cancer	9.46e-05	0.000361	CcSEcCtD
Auranofin—Pruritus—Methotrexate—breast cancer	9.45e-05	0.00036	CcSEcCtD
Auranofin—Urticaria—Doxorubicin—breast cancer	9.19e-05	0.00035	CcSEcCtD
Auranofin—Abdominal pain—Doxorubicin—breast cancer	9.15e-05	0.000349	CcSEcCtD
Auranofin—Diarrhoea—Methotrexate—breast cancer	9.14e-05	0.000349	CcSEcCtD
Auranofin—Pruritus—Epirubicin—breast cancer	8.85e-05	0.000337	CcSEcCtD
Auranofin—Diarrhoea—Epirubicin—breast cancer	8.55e-05	0.000326	CcSEcCtD
Auranofin—Vomiting—Methotrexate—breast cancer	8.49e-05	0.000324	CcSEcCtD
Auranofin—Rash—Methotrexate—breast cancer	8.42e-05	0.000321	CcSEcCtD
Auranofin—Dermatitis—Methotrexate—breast cancer	8.42e-05	0.000321	CcSEcCtD
Auranofin—Pruritus—Doxorubicin—breast cancer	8.19e-05	0.000312	CcSEcCtD
Auranofin—Vomiting—Epirubicin—breast cancer	7.95e-05	0.000303	CcSEcCtD
Auranofin—Nausea—Methotrexate—breast cancer	7.94e-05	0.000303	CcSEcCtD
Auranofin—Diarrhoea—Doxorubicin—breast cancer	7.92e-05	0.000302	CcSEcCtD
Auranofin—Rash—Epirubicin—breast cancer	7.88e-05	0.000301	CcSEcCtD
Auranofin—Dermatitis—Epirubicin—breast cancer	7.88e-05	0.0003	CcSEcCtD
Auranofin—Nausea—Epirubicin—breast cancer	7.43e-05	0.000283	CcSEcCtD
Auranofin—Vomiting—Doxorubicin—breast cancer	7.36e-05	0.00028	CcSEcCtD
Auranofin—Rash—Doxorubicin—breast cancer	7.29e-05	0.000278	CcSEcCtD
Auranofin—Dermatitis—Doxorubicin—breast cancer	7.29e-05	0.000278	CcSEcCtD
Auranofin—Nausea—Doxorubicin—breast cancer	6.87e-05	0.000262	CcSEcCtD
Auranofin—IKBKB—Signaling Pathways—FLT1—breast cancer	1.91e-05	7.29e-05	CbGpPWpGaD
Auranofin—IKBKB—Signaling Pathways—FGF3—breast cancer	1.9e-05	7.26e-05	CbGpPWpGaD
Auranofin—IKBKB—Signaling Pathways—SQSTM1—breast cancer	1.9e-05	7.26e-05	CbGpPWpGaD
Auranofin—ALB—Transmembrane transport of small molecules—ABCB1—breast cancer	1.9e-05	7.25e-05	CbGpPWpGaD
Auranofin—ALB—Platelet activation, signaling and aggregation—SRC—breast cancer	1.89e-05	7.2e-05	CbGpPWpGaD
Auranofin—ALB—Metabolism—CA9—breast cancer	1.88e-05	7.18e-05	CbGpPWpGaD
Auranofin—ALB—Metabolism—GSTA4—breast cancer	1.88e-05	7.18e-05	CbGpPWpGaD
Auranofin—IKBKB—Signaling Pathways—JAG1—breast cancer	1.88e-05	7.17e-05	CbGpPWpGaD
Auranofin—IKBKB—Signaling Pathways—PARP1—breast cancer	1.87e-05	7.14e-05	CbGpPWpGaD
Auranofin—IKBKB—Signaling Pathways—NOTCH3—breast cancer	1.87e-05	7.14e-05	CbGpPWpGaD
Auranofin—IKBKB—Adaptive Immune System—CDKN1B—breast cancer	1.86e-05	7.11e-05	CbGpPWpGaD
Auranofin—ALB—Metabolism of lipids and lipoproteins—GPX1—breast cancer	1.86e-05	7.09e-05	CbGpPWpGaD
Auranofin—IKBKB—Signaling Pathways—CALCA—breast cancer	1.85e-05	7.05e-05	CbGpPWpGaD
Auranofin—IKBKB—Innate Immune System—JUN—breast cancer	1.85e-05	7.04e-05	CbGpPWpGaD
Auranofin—ALB—Metabolism of lipids and lipoproteins—CYP1A1—breast cancer	1.84e-05	7.02e-05	CbGpPWpGaD
Auranofin—ALB—Platelet activation, signaling and aggregation—VEGFA—breast cancer	1.84e-05	7.01e-05	CbGpPWpGaD
Auranofin—ALB—Metabolism—GSTA2—breast cancer	1.84e-05	7e-05	CbGpPWpGaD
Auranofin—ALB—Metabolism—GPX2—breast cancer	1.84e-05	7e-05	CbGpPWpGaD
Auranofin—IKBKB—Innate Immune System—CTNNB1—breast cancer	1.83e-05	6.99e-05	CbGpPWpGaD
Auranofin—IKBKB—Signaling Pathways—RPS6—breast cancer	1.83e-05	6.97e-05	CbGpPWpGaD
Auranofin—ALB—Hemostasis—MMP1—breast cancer	1.82e-05	6.92e-05	CbGpPWpGaD
Auranofin—ALB—Metabolism—SULT1A1—breast cancer	1.81e-05	6.92e-05	CbGpPWpGaD
Auranofin—ALB—Metabolism—GPX4—breast cancer	1.81e-05	6.92e-05	CbGpPWpGaD
Auranofin—IKBKB—Signaling Pathways—FGF4—breast cancer	1.81e-05	6.91e-05	CbGpPWpGaD
Auranofin—IKBKB—Immune System—FGFR1—breast cancer	1.81e-05	6.91e-05	CbGpPWpGaD
Auranofin—IKBKB—Signaling Pathways—CXCR4—breast cancer	1.81e-05	6.89e-05	CbGpPWpGaD
Auranofin—IKBKB—Signaling Pathways—CXCL12—breast cancer	1.81e-05	6.89e-05	CbGpPWpGaD
Auranofin—IKBKB—Signaling by NGF—AKT1—breast cancer	1.81e-05	6.88e-05	CbGpPWpGaD
Auranofin—IKBKB—Innate Immune System—CDKN1A—breast cancer	1.79e-05	6.83e-05	CbGpPWpGaD
Auranofin—IKBKB—Immune System—BCL2L1—breast cancer	1.79e-05	6.83e-05	CbGpPWpGaD
Auranofin—IKBKB—Innate Immune System—PTEN—breast cancer	1.79e-05	6.81e-05	CbGpPWpGaD
Auranofin—ALB—Hemostasis—PLAU—breast cancer	1.78e-05	6.79e-05	CbGpPWpGaD
Auranofin—ALB—Hemostasis—CDK2—breast cancer	1.78e-05	6.79e-05	CbGpPWpGaD
Auranofin—IKBKB—Signaling Pathways—PAK1—breast cancer	1.77e-05	6.76e-05	CbGpPWpGaD
Auranofin—ALB—Metabolism—IDH1—breast cancer	1.77e-05	6.75e-05	CbGpPWpGaD
Auranofin—ALB—Metabolism—GSTA1—breast cancer	1.77e-05	6.75e-05	CbGpPWpGaD
Auranofin—ALB—Metabolism—NAT2—breast cancer	1.75e-05	6.68e-05	CbGpPWpGaD
Auranofin—IKBKB—Innate Immune System—MAPK8—breast cancer	1.75e-05	6.67e-05	CbGpPWpGaD
Auranofin—IKBKB—Signaling Pathways—TCF7L2—breast cancer	1.74e-05	6.64e-05	CbGpPWpGaD
Auranofin—ALB—Hemostasis—CAV1—breast cancer	1.74e-05	6.63e-05	CbGpPWpGaD
Auranofin—ALB—Platelet activation, signaling and aggregation—MAPK3—breast cancer	1.74e-05	6.63e-05	CbGpPWpGaD
Auranofin—IKBKB—Adaptive Immune System—CDKN1A—breast cancer	1.72e-05	6.56e-05	CbGpPWpGaD
Auranofin—IKBKB—Adaptive Immune System—PTEN—breast cancer	1.72e-05	6.54e-05	CbGpPWpGaD
Auranofin—ALB—Platelet activation, signaling and aggregation—TGFB1—breast cancer	1.69e-05	6.43e-05	CbGpPWpGaD
Auranofin—IKBKB—Signaling Pathways—NOTCH2—breast cancer	1.68e-05	6.4e-05	CbGpPWpGaD
Auranofin—IKBKB—Signaling Pathways—HSP90AA1—breast cancer	1.68e-05	6.4e-05	CbGpPWpGaD
Auranofin—IKBKB—Innate Immune System—SRC—breast cancer	1.66e-05	6.32e-05	CbGpPWpGaD
Auranofin—ALB—Hemostasis—FN1—breast cancer	1.66e-05	6.31e-05	CbGpPWpGaD
Auranofin—ALB—Hemostasis—NOS2—breast cancer	1.64e-05	6.24e-05	CbGpPWpGaD
Auranofin—IKBKB—Signaling Pathways—PRL—breast cancer	1.63e-05	6.23e-05	CbGpPWpGaD
Auranofin—IKBKB—Signaling Pathways—AGTR1—breast cancer	1.63e-05	6.23e-05	CbGpPWpGaD
Auranofin—IKBKB—Immune System—NFKBIA—breast cancer	1.62e-05	6.19e-05	CbGpPWpGaD
Auranofin—IKBKB—Signaling Pathways—STK11—breast cancer	1.61e-05	6.14e-05	CbGpPWpGaD
Auranofin—IKBKB—Signaling Pathways—ADAM10—breast cancer	1.61e-05	6.14e-05	CbGpPWpGaD
Auranofin—IKBKB—Signaling Pathways—PLG—breast cancer	1.59e-05	6.07e-05	CbGpPWpGaD
Auranofin—IKBKB—Adaptive Immune System—SRC—breast cancer	1.59e-05	6.07e-05	CbGpPWpGaD
Auranofin—ALB—Hemostasis—PIK3CG—breast cancer	1.59e-05	6.04e-05	CbGpPWpGaD
Auranofin—ALB—Metabolism of lipids and lipoproteins—CAV1—breast cancer	1.58e-05	6.04e-05	CbGpPWpGaD
Auranofin—IKBKB—Immune System—KIT—breast cancer	1.57e-05	5.99e-05	CbGpPWpGaD
Auranofin—ALB—Hemostasis—EGF—breast cancer	1.57e-05	5.97e-05	CbGpPWpGaD
Auranofin—IKBKB—Signaling Pathways—FGF10—breast cancer	1.57e-05	5.97e-05	CbGpPWpGaD
Auranofin—IKBKB—Immune System—EGF—breast cancer	1.55e-05	5.92e-05	CbGpPWpGaD
Auranofin—ALB—Metabolism—DPYD—breast cancer	1.54e-05	5.86e-05	CbGpPWpGaD
Auranofin—ALB—Metabolism—MED12—breast cancer	1.54e-05	5.86e-05	CbGpPWpGaD
Auranofin—IKBKB—Innate Immune System—MAPK3—breast cancer	1.53e-05	5.82e-05	CbGpPWpGaD
Auranofin—ALB—Metabolism—ALDOA—breast cancer	1.51e-05	5.76e-05	CbGpPWpGaD
Auranofin—IKBKB—Signaling Pathways—PDGFA—breast cancer	1.51e-05	5.76e-05	CbGpPWpGaD
Auranofin—IKBKB—Immune System—FOS—breast cancer	1.5e-05	5.71e-05	CbGpPWpGaD
Auranofin—IKBKB—Signaling Pathways—TGFBR2—breast cancer	1.49e-05	5.68e-05	CbGpPWpGaD
Auranofin—ALB—Metabolism—NCOA3—breast cancer	1.47e-05	5.6e-05	CbGpPWpGaD
Auranofin—IKBKB—Signaling Pathways—ITPR1—breast cancer	1.47e-05	5.59e-05	CbGpPWpGaD
Auranofin—IKBKB—Immune System—CASP8—breast cancer	1.46e-05	5.58e-05	CbGpPWpGaD
Auranofin—ALB—Metabolism—SLC2A2—breast cancer	1.46e-05	5.56e-05	CbGpPWpGaD
Auranofin—IKBKB—Signaling Pathways—ERBB4—breast cancer	1.46e-05	5.55e-05	CbGpPWpGaD
Auranofin—IKBKB—Signaling Pathways—MMP3—breast cancer	1.46e-05	5.55e-05	CbGpPWpGaD
Auranofin—IKBKB—Signaling Pathways—STAT5A—breast cancer	1.46e-05	5.55e-05	CbGpPWpGaD
Auranofin—IKBKB—Innate Immune System—EGFR—breast cancer	1.45e-05	5.54e-05	CbGpPWpGaD
Auranofin—ALB—Hemostasis—IGF1—breast cancer	1.45e-05	5.53e-05	CbGpPWpGaD
Auranofin—ALB—Hemostasis—AKT2—breast cancer	1.45e-05	5.53e-05	CbGpPWpGaD
Auranofin—IKBKB—Immune System—CDH1—breast cancer	1.45e-05	5.52e-05	CbGpPWpGaD
Auranofin—ALB—Metabolism of lipids and lipoproteins—PIK3CG—breast cancer	1.44e-05	5.5e-05	CbGpPWpGaD
Auranofin—IKBKB—Immune System—AKT2—breast cancer	1.44e-05	5.48e-05	CbGpPWpGaD
Auranofin—ALB—Platelet activation, signaling and aggregation—PIK3CA—breast cancer	1.44e-05	5.47e-05	CbGpPWpGaD
Auranofin—ALB—Metabolism—CPT1A—breast cancer	1.43e-05	5.44e-05	CbGpPWpGaD
Auranofin—ALB—Metabolism—MTR—breast cancer	1.43e-05	5.44e-05	CbGpPWpGaD
Auranofin—ALB—Metabolism—ABCG2—breast cancer	1.43e-05	5.44e-05	CbGpPWpGaD
Auranofin—IKBKB—Signaling Pathways—SMAD4—breast cancer	1.41e-05	5.38e-05	CbGpPWpGaD
Auranofin—IKBKB—Signaling Pathways—IGF1R—breast cancer	1.4e-05	5.34e-05	CbGpPWpGaD
Auranofin—ALB—Metabolism—HPGDS—breast cancer	1.4e-05	5.34e-05	CbGpPWpGaD
Auranofin—IKBKB—Adaptive Immune System—EGFR—breast cancer	1.4e-05	5.32e-05	CbGpPWpGaD
Auranofin—ALB—Hemostasis—PIK3CD—breast cancer	1.39e-05	5.31e-05	CbGpPWpGaD
Auranofin—ALB—Metabolism—HBA1—breast cancer	1.39e-05	5.31e-05	CbGpPWpGaD
Auranofin—IKBKB—Immune System—PIK3CD—breast cancer	1.38e-05	5.27e-05	CbGpPWpGaD
Auranofin—ALB—Hemostasis—SERPINE1—breast cancer	1.38e-05	5.25e-05	CbGpPWpGaD
Auranofin—IKBKB—Signaling Pathways—HES1—breast cancer	1.38e-05	5.25e-05	CbGpPWpGaD
Auranofin—IKBKB—Innate Immune System—KRAS—breast cancer	1.37e-05	5.23e-05	CbGpPWpGaD
Auranofin—IKBKB—Signaling Pathways—PLA2G4A—breast cancer	1.37e-05	5.22e-05	CbGpPWpGaD
Auranofin—IKBKB—Signaling Pathways—NCOR1—breast cancer	1.37e-05	5.22e-05	CbGpPWpGaD
Auranofin—ALB—Metabolism—ACHE—breast cancer	1.36e-05	5.18e-05	CbGpPWpGaD
Auranofin—ALB—Metabolism—GSTT1—breast cancer	1.36e-05	5.18e-05	CbGpPWpGaD
Auranofin—IKBKB—Signaling Pathways—CSF2—breast cancer	1.35e-05	5.16e-05	CbGpPWpGaD
Auranofin—IKBKB—Signaling Pathways—FGF1—breast cancer	1.35e-05	5.16e-05	CbGpPWpGaD
Auranofin—IKBKB—Signaling Pathways—NRG1—breast cancer	1.34e-05	5.12e-05	CbGpPWpGaD
Auranofin—IKBKB—Signaling Pathways—H2AFX—breast cancer	1.33e-05	5.09e-05	CbGpPWpGaD
Auranofin—IKBKB—Signaling Pathways—E2F1—breast cancer	1.33e-05	5.05e-05	CbGpPWpGaD
Auranofin—IKBKB—Adaptive Immune System—KRAS—breast cancer	1.32e-05	5.02e-05	CbGpPWpGaD
Auranofin—ALB—Hemostasis—NOS3—breast cancer	1.32e-05	5.01e-05	CbGpPWpGaD
Auranofin—ALB—Metabolism—CYP17A1—breast cancer	1.29e-05	4.9e-05	CbGpPWpGaD
Auranofin—ALB—Metabolism—PTGS1—breast cancer	1.27e-05	4.85e-05	CbGpPWpGaD
Auranofin—ALB—Metabolism—ENO1—breast cancer	1.27e-05	4.85e-05	CbGpPWpGaD
Auranofin—IKBKB—Signaling Pathways—SPP1—breast cancer	1.27e-05	4.85e-05	CbGpPWpGaD
Auranofin—ALB—Metabolism of lipids and lipoproteins—PIK3CD—breast cancer	1.27e-05	4.83e-05	CbGpPWpGaD
Auranofin—IKBKB—Innate Immune System—PIK3CA—breast cancer	1.26e-05	4.81e-05	CbGpPWpGaD
Auranofin—IKBKB—Signaling Pathways—ERBB3—breast cancer	1.26e-05	4.8e-05	CbGpPWpGaD
Auranofin—IKBKB—Signaling Pathways—FGFR2—breast cancer	1.26e-05	4.79e-05	CbGpPWpGaD
Auranofin—IKBKB—Immune System—BCL2—breast cancer	1.26e-05	4.79e-05	CbGpPWpGaD
Auranofin—ALB—Metabolism—CYP2D6—breast cancer	1.25e-05	4.76e-05	CbGpPWpGaD
Auranofin—IKBKB—Immune System—IFNG—breast cancer	1.25e-05	4.75e-05	CbGpPWpGaD
Auranofin—ALB—Hemostasis—RAF1—breast cancer	1.24e-05	4.74e-05	CbGpPWpGaD
Auranofin—IKBKB—Immune System—MDM2—breast cancer	1.24e-05	4.72e-05	CbGpPWpGaD
Auranofin—IKBKB—Immune System—RAF1—breast cancer	1.23e-05	4.7e-05	CbGpPWpGaD
Auranofin—IKBKB—Immune System—RELA—breast cancer	1.23e-05	4.68e-05	CbGpPWpGaD
Auranofin—ALB—Metabolism—NCOA2—breast cancer	1.23e-05	4.67e-05	CbGpPWpGaD
Auranofin—IKBKB—Immune System—ERBB2—breast cancer	1.22e-05	4.65e-05	CbGpPWpGaD
Auranofin—ALB—Hemostasis—PIK3CB—breast cancer	1.21e-05	4.63e-05	CbGpPWpGaD
Auranofin—IKBKB—Adaptive Immune System—PIK3CA—breast cancer	1.21e-05	4.62e-05	CbGpPWpGaD
Auranofin—IKBKB—Signaling Pathways—TERT—breast cancer	1.21e-05	4.6e-05	CbGpPWpGaD
Auranofin—IKBKB—Immune System—MTOR—breast cancer	1.21e-05	4.59e-05	CbGpPWpGaD
Auranofin—IKBKB—Immune System—PIK3CB—breast cancer	1.21e-05	4.59e-05	CbGpPWpGaD
Auranofin—IKBKB—Immune System—CD4—breast cancer	1.2e-05	4.58e-05	CbGpPWpGaD
Auranofin—ALB—Metabolism—FASN—breast cancer	1.19e-05	4.53e-05	CbGpPWpGaD
Auranofin—ALB—Metabolism—BCHE—breast cancer	1.18e-05	4.51e-05	CbGpPWpGaD
Auranofin—ALB—Platelet activation, signaling and aggregation—AKT1—breast cancer	1.17e-05	4.47e-05	CbGpPWpGaD
Auranofin—IKBKB—Signaling Pathways—FGFR1—breast cancer	1.17e-05	4.47e-05	CbGpPWpGaD
Auranofin—ALB—Metabolism—SLC5A5—breast cancer	1.17e-05	4.46e-05	CbGpPWpGaD
Auranofin—IKBKB—Innate Immune System—HRAS—breast cancer	1.17e-05	4.45e-05	CbGpPWpGaD
Auranofin—IKBKB—Signaling Pathways—HIF1A—breast cancer	1.15e-05	4.4e-05	CbGpPWpGaD
Auranofin—IKBKB—Immune System—CDKN1B—breast cancer	1.13e-05	4.31e-05	CbGpPWpGaD
Auranofin—ALB—Metabolism—NQO1—breast cancer	1.13e-05	4.3e-05	CbGpPWpGaD
Auranofin—ALB—Metabolism—SLC2A1—breast cancer	1.13e-05	4.3e-05	CbGpPWpGaD
Auranofin—IKBKB—Signaling Pathways—LEP—breast cancer	1.13e-05	4.29e-05	CbGpPWpGaD
Auranofin—IKBKB—Adaptive Immune System—HRAS—breast cancer	1.12e-05	4.27e-05	CbGpPWpGaD
Auranofin—IKBKB—Innate Immune System—IL6—breast cancer	1.12e-05	4.26e-05	CbGpPWpGaD
Auranofin—IKBKB—Signaling Pathways—CAV1—breast cancer	1.12e-05	4.25e-05	CbGpPWpGaD
Auranofin—ALB—Hemostasis—IL2—breast cancer	1.12e-05	4.25e-05	CbGpPWpGaD
Auranofin—IKBKB—Immune System—IL1B—breast cancer	1.11e-05	4.23e-05	CbGpPWpGaD
Auranofin—IKBKB—Immune System—IL2—breast cancer	1.11e-05	4.22e-05	CbGpPWpGaD
Auranofin—ALB—Metabolism of lipids and lipoproteins—PIK3CB—breast cancer	1.11e-05	4.21e-05	CbGpPWpGaD
Auranofin—IKBKB—Signaling Pathways—KDR—breast cancer	1.1e-05	4.21e-05	CbGpPWpGaD
Auranofin—ALB—Metabolism—CYP3A4—breast cancer	1.1e-05	4.2e-05	CbGpPWpGaD
Auranofin—ALB—Metabolism of lipids and lipoproteins—PTGS2—breast cancer	1.1e-05	4.18e-05	CbGpPWpGaD
Auranofin—ALB—Metabolism—CYP1B1—breast cancer	1.08e-05	4.13e-05	CbGpPWpGaD
Auranofin—ALB—Transmembrane transport of small molecules—RAF1—breast cancer	1.08e-05	4.1e-05	CbGpPWpGaD
Auranofin—IKBKB—Immune System—JUN—breast cancer	1.08e-05	4.1e-05	CbGpPWpGaD
Auranofin—IKBKB—Signaling Pathways—ESR1—breast cancer	1.08e-05	4.1e-05	CbGpPWpGaD
Auranofin—IKBKB—Immune System—CTNNB1—breast cancer	1.07e-05	4.07e-05	CbGpPWpGaD
Auranofin—IKBKB—Signaling Pathways—FN1—breast cancer	1.06e-05	4.05e-05	CbGpPWpGaD
Auranofin—ALB—Metabolism—HSP90AA1—breast cancer	1.06e-05	4.05e-05	CbGpPWpGaD
Auranofin—IKBKB—Signaling Pathways—NFKBIA—breast cancer	1.05e-05	4e-05	CbGpPWpGaD
Auranofin—IKBKB—Immune System—CDKN1A—breast cancer	1.04e-05	3.98e-05	CbGpPWpGaD
Auranofin—IKBKB—Immune System—PTEN—breast cancer	1.04e-05	3.97e-05	CbGpPWpGaD
Auranofin—IKBKB—Signaling Pathways—NOTCH1—breast cancer	1.04e-05	3.96e-05	CbGpPWpGaD
Auranofin—ALB—Metabolism—NCOA1—breast cancer	1.03e-05	3.94e-05	CbGpPWpGaD
Auranofin—IKBKB—Innate Immune System—AKT1—breast cancer	1.03e-05	3.93e-05	CbGpPWpGaD
Auranofin—IKBKB—Immune System—MAPK8—breast cancer	1.02e-05	3.88e-05	CbGpPWpGaD
Auranofin—ALB—Metabolism—STK11—breast cancer	1.02e-05	3.88e-05	CbGpPWpGaD
Auranofin—ALB—Metabolism—CYP19A1—breast cancer	1.02e-05	3.88e-05	CbGpPWpGaD
Auranofin—IKBKB—Signaling Pathways—PIK3CG—breast cancer	1.02e-05	3.87e-05	CbGpPWpGaD
Auranofin—IKBKB—Signaling Pathways—KIT—breast cancer	1.02e-05	3.87e-05	CbGpPWpGaD
Auranofin—IKBKB—Signaling Pathways—APC—breast cancer	1.02e-05	3.87e-05	CbGpPWpGaD
Auranofin—IKBKB—Signaling Pathways—EGF—breast cancer	1.01e-05	3.83e-05	CbGpPWpGaD
Auranofin—IKBKB—Adaptive Immune System—AKT1—breast cancer	9.89e-06	3.77e-05	CbGpPWpGaD
Auranofin—ALB—Hemostasis—SRC—breast cancer	9.73e-06	3.71e-05	CbGpPWpGaD
Auranofin—IKBKB—Immune System—SRC—breast cancer	9.66e-06	3.68e-05	CbGpPWpGaD
Auranofin—IKBKB—Signaling Pathways—BRAF—breast cancer	9.56e-06	3.64e-05	CbGpPWpGaD
Auranofin—ALB—Metabolism of lipids and lipoproteins—PTEN—breast cancer	9.55e-06	3.64e-05	CbGpPWpGaD
Auranofin—ALB—Hemostasis—VEGFA—breast cancer	9.48e-06	3.61e-05	CbGpPWpGaD
Auranofin—ALB—Metabolism—COMT—breast cancer	9.46e-06	3.61e-05	CbGpPWpGaD
Auranofin—ALB—Metabolism—GSTP1—breast cancer	9.42e-06	3.59e-05	CbGpPWpGaD
Auranofin—IKBKB—Immune System—STAT3—breast cancer	9.31e-06	3.55e-05	CbGpPWpGaD
Auranofin—IKBKB—Signaling Pathways—IGF1—breast cancer	9.31e-06	3.55e-05	CbGpPWpGaD
Auranofin—IKBKB—Signaling Pathways—AKT2—breast cancer	9.3e-06	3.55e-05	CbGpPWpGaD
Auranofin—ALB—Metabolism—HMOX1—breast cancer	9.29e-06	3.54e-05	CbGpPWpGaD
Auranofin—ALB—Metabolism—ITPR1—breast cancer	9.27e-06	3.53e-05	CbGpPWpGaD
Auranofin—ALB—Hemostasis—MAPK3—breast cancer	8.97e-06	3.42e-05	CbGpPWpGaD
Auranofin—IKBKB—Signaling Pathways—PIK3CD—breast cancer	8.94e-06	3.41e-05	CbGpPWpGaD
Auranofin—ALB—Metabolism—ABCB1—breast cancer	8.92e-06	3.4e-05	CbGpPWpGaD
Auranofin—IKBKB—Immune System—MAPK3—breast cancer	8.9e-06	3.39e-05	CbGpPWpGaD
Auranofin—IKBKB—Signaling Pathways—SERPINE1—breast cancer	8.84e-06	3.37e-05	CbGpPWpGaD
Auranofin—ALB—Metabolism—TYMS—breast cancer	8.76e-06	3.34e-05	CbGpPWpGaD
Auranofin—ALB—Hemostasis—TGFB1—breast cancer	8.7e-06	3.32e-05	CbGpPWpGaD
Auranofin—ALB—Metabolism—PLA2G4A—breast cancer	8.66e-06	3.3e-05	CbGpPWpGaD
Auranofin—ALB—Metabolism—GSTM1—breast cancer	8.66e-06	3.3e-05	CbGpPWpGaD
Auranofin—ALB—Metabolism—NCOR1—breast cancer	8.66e-06	3.3e-05	CbGpPWpGaD
Auranofin—IKBKB—Immune System—EGFR—breast cancer	8.46e-06	3.23e-05	CbGpPWpGaD
Auranofin—IKBKB—Signaling Pathways—NOS3—breast cancer	8.44e-06	3.22e-05	CbGpPWpGaD
Auranofin—ALB—Metabolism—GPX1—breast cancer	8.29e-06	3.16e-05	CbGpPWpGaD
Auranofin—ALB—Metabolism—CYP1A1—breast cancer	8.2e-06	3.13e-05	CbGpPWpGaD
Auranofin—ALB—Metabolism—ERCC2—breast cancer	8.14e-06	3.1e-05	CbGpPWpGaD
Auranofin—ALB—Hemostasis—KRAS—breast cancer	8.06e-06	3.07e-05	CbGpPWpGaD
Auranofin—IKBKB—Signaling Pathways—MDM2—breast cancer	8.01e-06	3.05e-05	CbGpPWpGaD
Auranofin—IKBKB—Immune System—KRAS—breast cancer	8e-06	3.05e-05	CbGpPWpGaD
Auranofin—IKBKB—Signaling Pathways—RAF1—breast cancer	7.98e-06	3.04e-05	CbGpPWpGaD
Auranofin—IKBKB—Signaling Pathways—RELA—breast cancer	7.94e-06	3.03e-05	CbGpPWpGaD
Auranofin—IKBKB—Signaling Pathways—ERBB2—breast cancer	7.89e-06	3.01e-05	CbGpPWpGaD
Auranofin—IKBKB—Signaling Pathways—MTOR—breast cancer	7.79e-06	2.97e-05	CbGpPWpGaD
Auranofin—IKBKB—Signaling Pathways—PIK3CB—breast cancer	7.79e-06	2.97e-05	CbGpPWpGaD
Auranofin—ALB—Metabolism—MTHFR—breast cancer	7.65e-06	2.92e-05	CbGpPWpGaD
Auranofin—IKBKB—Signaling Pathways—CXCL8—breast cancer	7.49e-06	2.85e-05	CbGpPWpGaD
Auranofin—ALB—Hemostasis—PIK3CA—breast cancer	7.4e-06	2.82e-05	CbGpPWpGaD
Auranofin—IKBKB—Immune System—PIK3CA—breast cancer	7.35e-06	2.8e-05	CbGpPWpGaD
Auranofin—IKBKB—Signaling Pathways—CDKN1B—breast cancer	7.31e-06	2.79e-05	CbGpPWpGaD
Auranofin—IKBKB—Signaling Pathways—CASP3—breast cancer	7.17e-06	2.73e-05	CbGpPWpGaD
Auranofin—ALB—Hemostasis—TP53—breast cancer	7.16e-06	2.73e-05	CbGpPWpGaD
Auranofin—IKBKB—Signaling Pathways—IL2—breast cancer	7.16e-06	2.73e-05	CbGpPWpGaD
Auranofin—ALB—Metabolism—CAV1—breast cancer	7.06e-06	2.69e-05	CbGpPWpGaD
Auranofin—IKBKB—Signaling Pathways—CCND1—breast cancer	6.98e-06	2.66e-05	CbGpPWpGaD
Auranofin—IKBKB—Signaling Pathways—JUN—breast cancer	6.96e-06	2.65e-05	CbGpPWpGaD
Auranofin—IKBKB—Signaling Pathways—CTNNB1—breast cancer	6.91e-06	2.63e-05	CbGpPWpGaD
Auranofin—ALB—Hemostasis—HRAS—breast cancer	6.85e-06	2.61e-05	CbGpPWpGaD
Auranofin—IKBKB—Immune System—HRAS—breast cancer	6.8e-06	2.59e-05	CbGpPWpGaD
Auranofin—IKBKB—Signaling Pathways—MMP9—breast cancer	6.77e-06	2.58e-05	CbGpPWpGaD
Auranofin—IKBKB—Signaling Pathways—CDKN1A—breast cancer	6.75e-06	2.57e-05	CbGpPWpGaD
Auranofin—ALB—Metabolism of lipids and lipoproteins—PIK3CA—breast cancer	6.74e-06	2.57e-05	CbGpPWpGaD
Auranofin—IKBKB—Signaling Pathways—PTEN—breast cancer	6.73e-06	2.57e-05	CbGpPWpGaD
Auranofin—IKBKB—Signaling Pathways—MAPK8—breast cancer	6.59e-06	2.51e-05	CbGpPWpGaD
Auranofin—IKBKB—Immune System—IL6—breast cancer	6.5e-06	2.48e-05	CbGpPWpGaD
Auranofin—ALB—Metabolism—PIK3CG—breast cancer	6.43e-06	2.45e-05	CbGpPWpGaD
Auranofin—IKBKB—Signaling Pathways—SRC—breast cancer	6.24e-06	2.38e-05	CbGpPWpGaD
Auranofin—IKBKB—Signaling Pathways—VEGFA—breast cancer	6.08e-06	2.32e-05	CbGpPWpGaD
Auranofin—ALB—Hemostasis—AKT1—breast cancer	6.05e-06	2.31e-05	CbGpPWpGaD
Auranofin—IKBKB—Signaling Pathways—STAT3—breast cancer	6.02e-06	2.29e-05	CbGpPWpGaD
Auranofin—IKBKB—Immune System—AKT1—breast cancer	6e-06	2.29e-05	CbGpPWpGaD
Auranofin—IKBKB—Signaling Pathways—MAPK3—breast cancer	5.75e-06	2.19e-05	CbGpPWpGaD
Auranofin—ALB—Metabolism—PIK3CD—breast cancer	5.65e-06	2.15e-05	CbGpPWpGaD
Auranofin—IKBKB—Signaling Pathways—MYC—breast cancer	5.59e-06	2.13e-05	CbGpPWpGaD
Auranofin—IKBKB—Signaling Pathways—TGFB1—breast cancer	5.58e-06	2.13e-05	CbGpPWpGaD
Auranofin—IKBKB—Signaling Pathways—EGFR—breast cancer	5.47e-06	2.09e-05	CbGpPWpGaD
Auranofin—ALB—Metabolism—NOS3—breast cancer	5.33e-06	2.03e-05	CbGpPWpGaD
Auranofin—IKBKB—Signaling Pathways—KRAS—breast cancer	5.17e-06	1.97e-05	CbGpPWpGaD
Auranofin—ALB—Metabolism—PIK3CB—breast cancer	4.92e-06	1.88e-05	CbGpPWpGaD
Auranofin—ALB—Metabolism—PTGS2—breast cancer	4.88e-06	1.86e-05	CbGpPWpGaD
Auranofin—IKBKB—Signaling Pathways—PIK3CA—breast cancer	4.75e-06	1.81e-05	CbGpPWpGaD
Auranofin—IKBKB—Signaling Pathways—TP53—breast cancer	4.59e-06	1.75e-05	CbGpPWpGaD
Auranofin—IKBKB—Signaling Pathways—HRAS—breast cancer	4.39e-06	1.67e-05	CbGpPWpGaD
Auranofin—ALB—Metabolism—PTEN—breast cancer	4.26e-06	1.62e-05	CbGpPWpGaD
Auranofin—IKBKB—Signaling Pathways—IL6—breast cancer	4.21e-06	1.6e-05	CbGpPWpGaD
Auranofin—IKBKB—Signaling Pathways—AKT1—breast cancer	3.88e-06	1.48e-05	CbGpPWpGaD
Auranofin—ALB—Metabolism—PIK3CA—breast cancer	3e-06	1.14e-05	CbGpPWpGaD
Auranofin—ALB—Metabolism—AKT1—breast cancer	2.45e-06	9.35e-06	CbGpPWpGaD
